These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 23434231)

  • 21. Recognizing and treating urogenital atrophy in postmenopausal women.
    Goldstein I
    J Womens Health (Larchmt); 2010 Mar; 19(3):425-32. PubMed ID: 20156082
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bazedoxifene/conjugated estrogens for menopausal symptom treatment and osteoporosis prevention.
    Pinkerton JV; Pickar JH; Racketa J; Mirkin S
    Climacteric; 2012 Oct; 15(5):411-8. PubMed ID: 22853444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical profile of women with vulvar and vaginal atrophy who are not candidates for local vaginal estrogen therapy.
    Nappi RE; Murina F; Perrone G; Villa P; Biglia N
    Minerva Ginecol; 2017 Aug; 69(4):370-380. PubMed ID: 28398023
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tissue-selective agents: selective estrogen receptor modulators and the tissue-selective estrogen complex.
    Pickar JH; Mirkin S
    Menopause Int; 2010 Sep; 16(3):121-8. PubMed ID: 20956688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing postmenopausal vaginal atrophy. Vaginal dryness is one of the most irritating symptoms of menopause. Here are some ways to relieve it.
    Harv Womens Health Watch; 2010 Mar; 17(7):4-5. PubMed ID: 20480969
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and tolerability of local estrogen therapy for urogenital atrophy.
    Archer DF
    Menopause; 2010; 17(1):194-203. PubMed ID: 19602990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Women's preferences toward attributes of local estrogen therapy for the treatment of vaginal atrophy.
    Mattsson LÅ; Ericsson Å; Bøgelund M; Maamari R
    Maturitas; 2013 Mar; 74(3):259-63. PubMed ID: 23312488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What new therapeutic options exist for the relief of menopausal symptoms?
    Raney EC
    JAAPA; 2015 Jul; 28(7):14-6. PubMed ID: 26107791
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cetyltrimethylammonium naproxenate as vaginal lavage in the therapy of vulvovaginal dystrophies in the postmenopause].
    Plotti G; Gozzi G; Bobbio C; Giulianelli G; Buttini G
    Minerva Ginecol; 1994 Oct; 46(10):583-6. PubMed ID: 7838418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen.
    Simon JA
    J Womens Health (Larchmt); 2011 Oct; 20(10):1453-65. PubMed ID: 21819250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ospemifene use in postmenopausal women.
    Gennari L; Merlotti D; Valleggi F; Nuti R
    Expert Opin Investig Drugs; 2009 Jun; 18(6):839-49. PubMed ID: 19466874
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ospemifene, a novel selective estrogen receptor modulator for treating dyspareunia associated with postmenopausal vulvar and vaginal atrophy.
    Portman DJ; Bachmann GA; Simon JA;
    Menopause; 2013 Jun; 20(6):623-30. PubMed ID: 23361170
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of estrogens and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women.
    Klein KP; Herrington DM
    Medscape Womens Health; 2002; 7(5):2. PubMed ID: 12466731
    [No Abstract]   [Full Text] [Related]  

  • 34. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Profile of ospemifene in the breast.
    Berga SL
    Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of Estrogens and Estrogen-Like Compounds in Female Sexual Function and Dysfunction.
    Santoro N; Worsley R; Miller KK; Parish SJ; Davis SR
    J Sex Med; 2016 Mar; 13(3):305-16. PubMed ID: 26944462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
    López-Belmonte J; Nieto C; Estevez J; Delgado JL; del Prado JM
    Maturitas; 2012 Aug; 72(4):353-8. PubMed ID: 22683083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of vaginal atrophy: a real mess. Results from the AGATA study.
    Palma F; Xholli A; Cagnacci A;
    Gynecol Endocrinol; 2017 Sep; 33(9):702-707. PubMed ID: 28391746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SERMs: progress and future perspectives.
    Pickar JH; MacNeil T; Ohleth K
    Maturitas; 2010 Oct; 67(2):129-38. PubMed ID: 20580502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical oxytocin reverses vaginal atrophy in postmenopausal women: a double-blind randomized pilot study.
    Jonasson AF; Edwall L; Uvnäs-Moberg K
    Menopause Int; 2011 Dec; 17(4):120-5. PubMed ID: 22120944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.